SC
ACAD icon

Shay Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Shay Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-28,563
Closed -$474K – 316
2025
Q1 		$474K Sell
28,563
-8,700
-23% -$158K 0.07% 156
2024
Q4 		$684K Buy
37,263
+18,830
+102% +$304K 0.1% 151
2024
Q3 		$284K Buy
18,433
+2,397
+15% +$40K 0.04% 223
2024
Q2 		$261K Buy
+16,036
New +$259K 0.04% 206

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Shay Capital's ACAD Position: Q2 2025 in Review

Shay Capital sold out of Acadia Pharmaceuticals (ACAD) in Q2 2025, closing a stake of 28,563 shares — an estimated $474K sold.

Shay Capital first reported a position in ACAD in Q2 2024 and held it in 4 quarters. The position peaked at $684K in Q4 2024. 311 funds tracked by Wall St. Rank hold ACAD as of Q2 2025.

  • Shay Capital reported no remaining Acadia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Shay Capital sold 28,563 Acadia Pharmaceuticals shares in Q2 2025, an estimated $474K.
  • Shay Capital first reported a position in Acadia Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Shay Capital's Acadia Pharmaceuticals position peaked at $684K in Q4 2024.
  • 311 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2025.

Based on Shay Capital's 13F filing for Q2 2025, filed 14 Aug 2025.